chrisvoncsefalvay/vaers-outcomes huggingface dataset:
She reports that approximately one hour after receiving her second Moderna COVID19 mRNA vaccine she developed itching over her chest, abdomen, and anterior thighs associated with subjective tongue swelling. Her symptoms lasted for approximately 6-7 hours and resolved without treatment. She reports that approximately 30 minutes after she received her Moderna COVID19 mRNA vaccine booster dose she developed itching and redness of her arms that resolved spontaneously without treatment. She denies generalized cutaneous, laryngeal, pulmonary, GI/GU, neurologic, and cardiovascular symptoms with these episodes.
I had a scratchy throat. I took an at home test that was negative. I was taking Mucinex and using a Netty Pot to deal with the symptoms. I still was not feeling well and I took another COVID test on Sunday and it was positive. I did not have a fever or lose my sense of taste or smell. I primarily have congestion in my chest. On Wednesday, I went to have the monoclonal antibody treatment. I am still suffering from congestion and fatigue. I had a telehealth appointment on Monday and the provider recommended that I get the antibodies which I got on Wednesday.
Moderna COVID-19 Vaccine - dose given 16 days after BUD for refrigeration
Mother asked nurse to check other child's arm at 5:30PM she states she had not checked Rt deltoid is swollen, slight redness noted, firm to touch and tender swelling size is greater than a 50 cent piece. T 96.8. Referred for evaluation 10/5/04 ER physician evaluated and ordered Tylenol and Motrin 94hrs. 10/8/04 mother states swelling almost gone.
This is a spontaneous report from a contactable consumer or other non hcp. Follow-up (PRD: 18May2021) received from a contactable consumer or other non hcp was processed together with initial information. A patient of unspecified age and gender received BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number and expiration date was not reported), dose 1 via an unspecified route of administration on an unspecified date as 1st dose, single for COVID-19 immunization. The patient medical history, concomitant medications were not reported. On an unspecified date, the patient reported that patient was having serious like mental problem, started having really bad forgetfulness and anxiety; that was just crippling anxiety and ridiculous forgetfulness, patient couldn't function properly, patient felt like it was dangerous, and patient can't even run business right now. The outcome of events was unknown. Patient reported that two other contractors that patient worked with electrician and tile guy both experiencing the same symptoms like the patient, they were frustrated because they were forgetting everything and they felt awkward around customers because the brain could function barely. Patient also reported that the cousin had the same reactions. Cousin had been a hairstylist for years and she messed the 3 hair colors that she had never done in most 20 years of coloring hair and she couldn't remember anything. She got crippling anxiety, she got her second shot and then on day 4 after her second shot all the symptoms gone away then she got better. Information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021559009 same drug/AE, different patient;US-PFIZER INC-2021558925 same drug/AE,different patient
Headache, Myalgia, Fever, NauseaVomiting, facial swelling, had dental procedure the same day Narrative:  had dental procedure the same day, missed a day of work
Headache; Dizziness; This is a spontaneous report from a non-contactable other healthcare professional, the patient. A 20-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20Feb2021 at 13:00 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included dexmethylphenidate hydrochloride (FOCALIN) and escitalopram oxalate (LEXAPRO); both for unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Jan2021 at 13:00 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. On 22Feb2021 at 12:00, the patient experienced headache and dizziness after the second shot. Since the vaccination, the patient had been tested for COVID-19. On 22Feb2021, the patient underwent work COVID-19 test via nasal swab and the result was pending. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether therapeutic measures were taken as a result of the events. The clinical outcome of the events headache and dizziness after the second shot was unknown at the time of this report. No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
After 7 hours he developed funny taste out of stomach when he belches; developed funny taste out of stomach when I belche; This spontaneous case was reported by a consumer and describes the occurrence of ERUCTATION (After 7 hours he developed funny taste out of stomach when he belches) and TASTE DISORDER (developed funny taste out of stomach when I belche) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Dec-2021 at 11:00 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Dec-2021, the patient experienced ERUCTATION (After 7 hours he developed funny taste out of stomach when he belches) and TASTE DISORDER (developed funny taste out of stomach when I belche). At the time of the report, ERUCTATION (After 7 hours he developed funny taste out of stomach when he belches) and TASTE DISORDER (developed funny taste out of stomach when I belche) outcome was unknown.            No Concomitant medication was reported.     No treatment medications were reported.   Reporter did not allow further contact
pt recv vax & devel lt axillary lymphadenopathy;pt has been exp lt ax pain, which radiates to the lt breast;reporter attributed the pain to the lymphadenopathy;
COVID BOOSTER VACCINE WAS GIVEN 18 DAYS TOO EARLY.  PATIENT DID NOT HAVE ANY SYMPTOMS AND DOCTOR DECIDED TO NOT RE-VACCINATE.
Severe itching; heat at vaccine site; red rash; painful to touch; feels like a knot under skin.
T103.8, poor color, gagging on nasal discharge;resolved w/in 24hr reporter states highest fever seen w/DTAP;
c/o "sick for several days, didn't start for a few days. nausea the day of the shot. had to stop the car and get out and walk" after vaccination.
rash on his arm and on his left foot that is stinging and painful; rash on his arm and on his left foot that is stinging and painful; rash on his arm and on his left foot that is stinging and painful; burning and tingling sensation during the night; burning and tingling sensation during the night; This is a spontaneous report from a contactable consumer (patient) via medical information team. A male patient of an unspecified age (reported as Age:80, Unit: Unknown) reported for himself that he received bnt162b2 (PFIZER COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 19Feb2021 as DOSE 2, SINGLE for covid-19 immunisation. Medical history included poison ivy rash from an unknown date and unknown if ongoing (Caller states his is also very susceptible to poison ivy which is a similar rash, and is usually treated with steroid packs). The concomitant medications were not reported. The patient previously took first dose of bnt162b2 (Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient had received both of the bnt162b2 vaccines. On 27Feb2021, 8 days later the second dose, the patient developed a rash on his arm and on his left foot that is stinging and painful, especially during the night. And also this morning, on 01Mar2021, he noticed a rash on his left foot, on the top of the foot. The patient stated that there was burning and tingling sensation during the night. He was wondering if that was known side effect of the product, and if he should be tested for covid in anyway. Investigation assessment was not provided. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This is a spontaneous report from a Pfizer-sponsored program received from a contactable consumer reporting for her/himself. A patient of unspecified age ethnicity and gender received PREVNAR 13, via an unspecified route of administration, on an unspecified date in 2015, at single dose, for immunisation. The patient's medical history and concomitant medications were not reported. The patient was very sick the week before report and went to the doctor, then to the emergency room at the hospital because she/he couldn't breathe. The patient was diagnosed with pneumonia. Outcome of the event was unknown.
about 2 hours after pediarix, prevnar and Hib vaccine, became limp would not eat or interact, lasted for 2 hours then cried unconsolably for x's 2 hours then red blotches that itched x's 2 hours, then woke up limp again-total time of acting abnormal was 21 hours then normal, Temp 99.  Suspect HHE due to Dtap. Gave DT on 6-10-08 without problems.
Mild case of shingles; Mild case of shingles; Skin rash; This case was reported by a consumer and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 22nd July 2018, the patient received the 1st dose of Shingrix. On 20th November 2018, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and rash. On an unknown date, the outcome of the vaccination failure, shingles and rash were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and rash to be related to Shingrix and Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient recently had a skin rash, he/she took pictures of it and sent them to internist. The internist said that it could be several things, one of which was a mild case of shingles. The patient did a one week course of a little reading and saw that Shingrix was about 90% effective he/she also seen 4 years mentioned regarding efficacy. The patient wanted to know about the 10% for whom Shingrix was not effective. For example, did they tend to get only mild cases of shingles. The patient wanted to know the recommendations for re-vaccination, such as after what time period.
About 15 minutes after the shot, I noticed my skin was turning red on my hands and my knuckles were turning white.  I was treated with an antihistamine. Waited 20 minutes more and the reaction subsided.
Patient is a 68 y.o. female with a past medical history notable for breast cancer with metastasis to stomach, liver, bone, hilum currently on palliative therapy with treatment focus who presented to the urgent care due to confusion.   In the ED she was found to have hypoxia and tachycardia.  She required 4-5 L nasal cannula.  Labs were notable for alk-phos 105, ALT 50, T bili 0.7, electrolytes within normal limits, creatinine at baseline, lactic acid 1.6, WBC 10.5 with a left shift, procalcitonin 2.18, D-dimer 2167.  COVID was positive.  Chest x-ray showed right upper and right middle lobe infiltrate with enlarged hilar area (possible reactive lymphadenopathy).  CT head showed no acute abnormalitie. CT abdomen and pelvis only noted bilateral lower airspace disease compatible with pneumonia.
Patient developed globus sensation, chest tightness, and dizziness shortly after vaccination.  Observed for 2 hours without concern, and was discharged without further issue.
Perfectly healthy when went in for vaccine. No sickness. High fever for days (104-104.5) through the 26th. Extremely lethargic and fussy. Called in and went in for x-ray, thickening in lungs. Flu-like symptoms. Immediately following vaccine administration noticable speech regression by all close to Kaylea and has not recovered yet as of April 23, 2019.
pt had high fever & diarrhea w/in hrs of vax; went to home to get fever down; also exhibited a high pitched scream cry that was not continual but present for several hrs; seen in hosp ER;
Within the next three days i had a high fever of 102f, soreness at the injection site. On the second dose (on 4/28/21) I had that and shivering, sweating, fatigue, body aches that lasted about 1 day after they started and were gone by the third morning after getting the second shot.  Since the second vaccine and ongoing I have developed a heavy mucus buildup and need to clear my throat often, periodically (perhaps once a week for a couple hours) I cough up grey/green sputum. No other symptoms are present as far as I can tell and I am not running any fever. I have scheduled a virtual appointment with my primary care provider later today.
Severe pain at injection site and throughout arm by morning following injection. Physical Therapy began 6 weeks following injection. Cortizone shot given 2.5 months following injection.
Around 9pm began have extreme chills and aches. Could not sleep. Still have chills, aches and a migraine. Was so uncomfortable didn?t get out of bed until 2. Took extra strength Tylenol at 6:30. Did nothing for headache and chills came back at 10:30. Took Norco at 12:30 and was able to get a little sleep. Woke up and felt good enough to get out of bed and check temp. Temperature was 102.2 at 3:00. I think my temperature was well over 102 last night because of how uncomfortable I was.
Patient was mistakenly triaged for 12+ grey bivalent pfizer covid booster. Patient should have been triaged for and received orange 5-11 year old pfizer covid booster. Patient not treated at time of event, no ade observed. Parent and pt informed to monitor for ade and to report any that occur.
I thought I felt better this morning and went to the gym, couldnt stay (didnt feel well); It is worsened when I got up this morning and right now I am staying the same; yesterday I was achy; chills; rash on front and back of feet and legs (below knees); red rash face (cheeks); body temperature was still down, it's cold/ Caller says her body temperature with thermal scanner is at 93 degrees; This is a spontaneous report from a contactable consumer (patient). A 74-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTEC COVID-19 VACCINE, Solution for injection, Lot Number: EJ1686) via Intramuscular in arm on 02Feb2021 at 15:00 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. Medical history included thyroid. Concomitant medication included levothyroxine for thyroid ongoing since 2014, fish oil, vitamin E NOS (Mega Red Omega - 3's) and calcium (ORGANIC PLANT CALCIUM) ongoing since 2018, colecalciferol (D3) and magnesium ongoing since 2019; calcium (GROW BONE CALCIUM) for strengthen from 19Jan2021 to 02Feb2021 and growth factors for bones from 19Jan2021 to 02Feb2021. Medication within two weeks included levothyroxine, Mega Red Omega - 3's, calcium(ORGANIC PLANT CALCIUM, GROW BONE CALCIUM), colecalciferol (D3) and magnesium and growth factors for bones. On 02Feb2021, the patient had a red rash on face (cheeks) and rash on front and back of feet and legs (below knees), body temperature was still down, it's cold. Patient's body temperature was done with thermal scanner was at 93 degrees. The thermal scanner at the gym was reading "low" and did not provide a temperature reading. Temperature has not been obtained any other manner. On 03Feb2021, patient was achy and had chills. On 04Feb2021, patient thought felt better and went to the gym, couldnt stay (didnt feel well). says (only thermal/oral reading not attempted). Patient was still experiencing the events, she was still cold and have the rash. It was worsened when got up this morning and right now staying the same. Patient was cold and just red. Patient went to bed last night with the rash and woke up this morning it was the same. Her body temperature was still down, it was cold. On unspecified date in Feb 2021, body temperature was 91. Patient had received second dose of vaccine (Batch/Lot number: EJ1686) via intramuscularly on 23Feb2021 at 10:30 as a single dose for COVID-19 immunisation. The outcome for event red rash face (cheeks), rash on front and back of feet and legs (below knees), body temperature was still down, it's cold was not recovered and for other events was unknown.  Follow-up attempts are completed. No further information is expected.
Severe headache, Chills, Body ache , chest discomfort, nausea/ vomiting up bile , scratchy throat and dry cough.
Patient developed severe large hives over entire body. Also she developed fever of 102. She was treated with Benadryl 50mg for 2 days without resolution of her symptoms. Prednisone 80mg was started on the night of the 2nd day in the ER. Hydroxazine 25mg was given instead of the Benadryl on the 3rd day. The symptoms resolved and treatment was stopped on day 7.
Unspecified adverse effect of drug or medicament, initial encounter R51.9Headache, unspecified reported this to support team to complete VAERS. Patient aware. Not sure yet if related to vaccine versus other etiology. Please be seen in person in urgent care today for further work up."
Broke out in hives on 10/2/2019 and call the health Department on 10/3/2019.  Public Health Nurse went out to day care to check on 10/3/2019 and there was no more rash/hives and the injection site was clear.
Patients received Monovalent Moderna Vaccine past the manufacturers expiration date; No adverse event; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patients received Monovalent Moderna Vaccine past the manufacturers expiration date) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patients received Monovalent Moderna Vaccine past the manufacturers expiration date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patients received Monovalent Moderna Vaccine past the manufacturers expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            No concomitant drug information was provided.  It was reported that there were 3 lot numbers. Lot 022D21A with expiration 20Apr2022, Lot 033F21A with expiration 08Apr2022 and Lot 037C21A with expiration 2Jan2022.  In total 30 doses were administered with 13, 11, and 6 different doses from different lot numbers.      No treatment medication information was provided.  The case was reported for 4th out  of 30 adult patients who had received the vaccine as reported by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-703461; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-703461:master case
had a little bump in her arm and she feels movable; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (159558). The reporter is the parent.  A female patient received bnt162b2 (BNT162B2), administration date 25Mar2021 (Batch/Lot number: unknown) as dose 2, single and administration date 03Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SKIN DISORDER (non-serious), outcome "unknown", described as "had a little bump in her arm and she feels movable".  No follow-up attempts are possible. No further information is expected.
I had the booster shot in October 2021, but developed Covid on April 11, 2022. Symptoms included high fever, sore throat, cough, general maiaise. Fever lasted sever days, cough persisted for 10 plus days and lethargy continued for 10 plus days.
Tiredness; Temperature 99.6F higher than usually which is 96-97F; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration on 02Apr2021 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have any known allergy to any medications, food, or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 12Mar2021 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021, the patient experienced tiredness and temperature (99.6F)(Fahrenheit) which was higher than usual which was 96-97F. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events tiredness and temperature (99.6F). The clinical outcomes of the events tiredness and temperature (99.6F) were resolved on unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Pt. received influenza vaccine at work place clinic on 11/14/19 at 3:40pm and states that by the time he got home that evening noticed he was itchy on his arms b/l and then stomach and back and thighs and when he looked noted pink small hives which persist today. Pt. came in to report his symptoms and for evaluation to clinic on 11/15/19. Hives itchy but remain stable. Self treated with Zyrtec and Benadryl which helped with itching. Denies any oral/facial swelling, difficulty breathing, SOB, CP,  wheezing, N/V, Abdominal cramping.
This case was reported by a nurse via sales rep and described the occurrence of herpes zoster in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, 21 days after receiving SHINGRIX, the patient experienced herpes zoster. On an unknown date, the outcome of the herpes zoster was unknown. It was unknown if the reporter considered the herpes zoster to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. Approximately 3 weeks after receiving SHINGRIX, the patient experienced herpes zoster on chin. The patient's initials and date of birth was unknown. The nurse agreed to receive follow up from GlaxoSmithKline.